Clinical Trials
13 trialsNCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03496766 2025-03-05
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
Phase 2 Terminated
NCT02807272 2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2 Completed
NCT02383927 2024-07-11
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
Phase 2 Completed
NCT02464228 2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2 Completed
NCT03719690 2024-06-21
AIM-HN/SEQ-HN
Kura Oncology, Inc.
Phase 2 Completed
NCT00082888 2020-04-13
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082810 2018-11-01
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01361464 2015-04-08
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00602771 2014-10-09
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00281957 2014-05-20
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed